Business UpdateJun 8, 2026, 02:47 PM
Oculis to Present Pipeline Update at Goldman Sachs Healthcare Conference
AI Summary
Oculis Holding AG announced its management will participate in a fireside chat at the 47th Annual Goldman Sachs Global Healthcare Conference on June 9. CEO Dr. Riad Sherif will provide an overview and update on its late-stage portfolio, including Privosegtor, which has received Breakthrough Therapy and PRIME designations for optic neuritis, targeting a $7B+ U.S. market. The presentation will also cover Licaminlimab, a topical treatment for dry eye disease in a registrational trial. Oculis highlighted its strong balance sheet and advanced pipeline, preparing for several pivotal readouts with current funding.
Key Highlights
- Oculis management to participate in fireside chat at Goldman Sachs Global Healthcare Conference.
- CEO Dr. Riad Sherif to present on June 9, 4:00pm ET, providing a pipeline update.
- Privosegtor received FDA Breakthrough Therapy and EMA PRIME designations for optic neuritis.
- Privosegtor targets a potential U.S. market opportunity exceeding $7 billion.
- Licaminlimab is in the PREDICT-1 registrational trial for dry eye disease.
- Company has a strong balance sheet and advanced pipeline for pivotal readouts.
Price Impact
More from OCS